The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment:a systematic review  

作　　者：Amirhosein Sabaghian Shahnam Shamsabadi Saghar Momeni Mobina Mohammadikia Kiarash Mohebbipour Samira Sanami Sajjad Ahmad Nahid Akhtar Neeta Raj Sharma Raja Babu Singh Kushwah Yash Gupta Ajit Prakash Hamidreza Pazoki-Toroudi 

机构地区：[1]Physiology Research Center&Department of Physiology,Faculty of Medicine,Iran University of Medical Sciences,Tehran,Iran [2]Abnormal Uterine Bleeding Research Center,Semnan University of Medical Sciences,Semnan,Iran [3]Department of Health and Biological Sciences,Abasyn University,Peshawar 25000,Pakistan [4]Gilbert and Rose-Marie Chagoury School of Medicine,Lebanese American University,Beirut P.O.Box 36,Lebanon [5]Department of Natural Sciences,Lebanese American University,Beirut P.O.Box 36,Lebanon [6]School of Bioengineering and Biosciences,Lovely Professional University,Phagwara 144411,India [7]Department of Entomology,Texas A&M University,College Station,TX 77843,USA [8]Department of Medicine,Penn State College of Medicine,Hershey,PA 17033,USA [9]Department of Biochemistry and Biophysics,University of North Carolina,Chapel Hill,NC 27599,USA

出　　处：《Journal of Cancer Metastasis and Treatment》2024年第1期445-477,共33页癌症转移与治疗(英文版)

摘　　要：Aim:Cancer as a complex disease poses significant challenges for both diagnosis and treatment.Researchers have been exploring various avenues to find effective therapeutic strategies,with a particular emphasis on cellular signaling pathways and immunotherapy.One such pathway that has recently been suggested is the PD-1/PD-L1 pathway,which is an immune checkpoint signaling system that plays an important role in regulating the immune system and maintaining tissue homeostasis.Cancer cells exploit this pathway by producing PD-L1,which attaches to PD-1 on T cells,thus inhibiting immune responses and enabling the cancer cells to escape detection by the immune system.This study aimed to evaluate the role of the PD-1/PD-L1 pathway in cancer pathogenesis and treatment.Method:This study was performed based on the principles of Preferred Reporting Items for Systematic Reviews and Meta-Analysis(PRISMA).All in vitro,in vivo,and clinical studies that were published in English have been considered during a thorough search of the Scopus,Web of Science,and PubMed databases without date restriction until March 2024.Results:According to the studies reviewed,the PD-1/PD-L1 signaling axis suggests promising therapeutic effects on various types of cancers such as non-small cell lung cancer,melanoma,breast cancer,hepatocellular carcinoma,squamous cell carcinoma,and colorectal cancer,among others.Additionally,research suggests that immune checkpoint inhibitors that block PD1/PD-L1,such as pembrolizumab,atezolizumab,nivolumab,durvalumab,cemiplimab,avelumab,etc.,can effectively prevent tumor cells from escaping the immune system.Moreover,there might be a possible interaction between microbiome,obesity,etc.on immune mechanisms and on the immune checkpoint inhibitors(ICIs).Conclusion:Although we have gained considerable knowledge about ICIs,we are still facing challenges in effectively prescribing the appropriate ICIs for individual patients.This is largely due to the complex interactions between different intracellular pathways,which need

关 键 词：PD-1/PD-L1 pathway CANCER IMMUNOTHERAPY immune checkpoint inhibitors 

分 类 号：R73[医药卫生—肿瘤]